Innoviva - Stock Split History | INVA

Stock split history for Innoviva since 2020. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Innoviva Annual Stock Splits
Innoviva Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.164B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $339.589B 14.84
Roche Holding AG (RHHBY) Switzerland $279.418B 0.00
Merck (MRK) United States $187.177B 14.22
Novartis AG (NVS) Switzerland $185.475B 15.44
Pfizer (PFE) United States $176.138B 10.76
Novo Nordisk (NVO) Denmark $141.488B 24.29
Eli Lilly (LLY) United States $130.559B 22.59
Bristol-Myers Squibb (BMY) United States $123.757B 11.74
AstraZeneca (AZN) United Kingdom $114.895B 24.73
AbbVie (ABBV) United States $108.417B 8.21
Sanofi (SNY) France $107.453B 12.77
GlaxoSmithKline (GSK) United Kingdom $92.874B 11.78
Bayer (BAYRY) Germany $52.894B 7.62
H Lundbeck (HLUYY) Denmark $5.897B 10.25